Design, synthesis, radiolabeling and biological evaluation of new urea-based peptides targeting prostate specific membrane antigen.
Antigens, Surface
/ analysis
Dose-Response Relationship, Drug
Drug Design
Glutamate Carboxypeptidase II
/ analysis
Humans
Male
Models, Molecular
Molecular Structure
Neoplasms, Experimental
/ diagnostic imaging
PC-3 Cells
Peptides
/ chemical synthesis
Prostatic Neoplasms
/ diagnostic imaging
Single Photon Emission Computed Tomography Computed Tomography
Structure-Activity Relationship
Technetium
/ chemistry
Urea
/ analogs & derivatives
PSMA
Peptide
Prostate cancer
Technetium-99m
Journal
Bioorganic chemistry
ISSN: 1090-2120
Titre abrégé: Bioorg Chem
Pays: United States
ID NLM: 1303703
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
09
10
2019
revised:
01
03
2020
accepted:
07
03
2020
pubmed:
29
3
2020
medline:
24
2
2021
entrez:
29
3
2020
Statut:
ppublish
Résumé
Early diagnosis of Prostate cancer (PCa) plays a vital role in successful treatment increasing the survival rate of patients. Prostate Specific Membrane Antigen (PSMA) is over-expressed in almost all types of PCa. The goal of present study is to introduce new
Identifiants
pubmed: 32217372
pii: S0045-2068(19)31692-X
doi: 10.1016/j.bioorg.2020.103743
pii:
doi:
Substances chimiques
Antigens, Surface
0
Peptides
0
Technetium
7440-26-8
Urea
8W8T17847W
FOLH1 protein, human
EC 3.4.17.21
Glutamate Carboxypeptidase II
EC 3.4.17.21
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
103743Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.